Indivior PLC (NASDAQ:INDV) Short Interest Up 9.9% in December

Indivior PLC (NASDAQ:INDV) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 1,220,000 shares, a growth of 9.9% from the December 15th total of 1,110,000 shares. Based on an average trading volume of 1,280,000 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.1% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on INDV. Craig Hallum lowered their target price on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday, October 11th. Piper Sandler reiterated an “overweight” rating and set a $16.00 price objective (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Stock Down 0.1 %

INDV traded down $0.01 on Friday, reaching $11.65. 1,060,388 shares of the company traded hands, compared to its average volume of 974,047. Indivior has a one year low of $7.33 and a one year high of $23.22. The firm has a fifty day simple moving average of $11.46 and a two-hundred day simple moving average of $11.07. The company has a market cap of $1.61 billion, a P/E ratio of -291.18 and a beta of 0.74.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. The company had revenue of $307.00 million during the quarter, compared to analyst estimates of $302.25 million. On average, equities analysts forecast that Indivior will post 1.62 earnings per share for the current year.

Institutional Investors Weigh In On Indivior

Several large investors have recently modified their holdings of INDV. Stifel Financial Corp bought a new stake in shares of Indivior in the 3rd quarter valued at about $100,000. Melqart Asset Management UK Ltd bought a new stake in shares of Indivior in the 3rd quarter valued at about $132,000. Jane Street Group LLC bought a new stake in shares of Indivior in the 3rd quarter valued at about $180,000. Bank of New York Mellon Corp bought a new stake in shares of Indivior in the 2nd quarter valued at about $188,000. Finally, XTX Topco Ltd bought a new stake in shares of Indivior in the 2nd quarter valued at about $249,000. Institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.